Anticancer chemotherapy.
作者信息
Davey P, Tudhope G R
出版信息
Br Med J (Clin Res Ed). 1983 Jul 9;287(6385):110-3. doi: 10.1136/bmj.287.6385.110.
Abstract
摘要
相似文献
1
Anticancer chemotherapy.抗癌化疗
Br Med J (Clin Res Ed). 1983 Jul 9;287(6385):110-3. doi: 10.1136/bmj.287.6385.110.
2
[New substances in oncologic therapy].
Dtsch Med Wochenschr. 1978 Jul 7;103(27):1087-92. doi: 10.1055/s-0028-1129206.
3
[New substances in oncologic therapy].
Schweiz Med Wochenschr. 1978 Aug 12;108(32):1222-7.
4
Antineoplastic chemotherapy.
South Med J. 1977 Jul;70(7):847-54. doi: 10.1097/00007611-197707000-00025.
5
Investigational drugs under study by the United States National Cancer Institute.
Cancer Treat Rev. 1976 Mar;3(1):43-60. doi: 10.1016/s0305-7372(76)80016-3.
6
Chemotherapy in gynecological malignancies--and its nursing aspects.妇科恶性肿瘤的化疗及其护理要点
JOGN Nurs. 1976 Sep-Oct;5(5):9-14. doi: 10.1111/j.1552-6909.1976.tb02331.x.
7
[Chemotherapy of lymphogranulomatosis].
Sov Med. 1979 Aug(8):86-90.
8
Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.晚期肺腺癌的单药化疗。综述。
Cancer Chemother Pharmacol. 1988;21(2):89-102. doi: 10.1007/BF00257354.
9
Management of Kaposi's sarcoma. Chemotherapy I.卡波西肉瘤的治疗。化疗I。
Antibiot Chemother (1971). 1981;29:82-7.
10
Hungarian anticancer drugs (antineoplastics).
Ther Hung. 1982;30(3):110-21.
引用本文的文献
1
3D tissue-engineered model of Ewing's sarcoma.尤因肉瘤的3D组织工程模型
Adv Drug Deliv Rev. 2014 Dec 15;79-80:155-71. doi: 10.1016/j.addr.2014.07.012. Epub 2014 Aug 7.
本文引用的文献
1
The acute toxicities of chemotherapy.化疗的急性毒性
Cancer Treat Rev. 1981 Sep;8(3):197-207. doi: 10.1016/s0305-7372(81)80017-5.
2
The scientific basis for adjuvant chemotherapy.辅助化疗的科学依据。
Cancer Treat Rev. 1981 Sep;8(3):169-89. doi: 10.1016/s0305-7372(81)80015-1.
3
Cancer chemotherapy: new developments and changing concepts.癌症化疗：新进展与观念转变
Drugs. 1980 Nov;20(5):375-97. doi: 10.2165/00003495-198020050-00003.
4
VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
Am J Med. 1982 Jan;72(1):136-44. doi: 10.1016/0002-9343(82)90600-3.
5
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential.生物反应调节剂与辅助化疗：关于与临床潜力相关的部分临床前研究的考量
Recent Results Cancer Res. 1982;80:351-6. doi: 10.1007/978-3-642-81685-7_57.
6
ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
Cancer Treat Rev. 1976 Jun;3(2):95-107. doi: 10.1016/s0305-7372(76)80007-2.
7
Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
Cancer Treat Rep. 1979 Mar;63(3):501-5.
Zotero 插件